BridgeBio Pharma reported impressive Q2 2026 net revenues of $243.7 million, more than doubling last year's $110.6 million despite competitive pressures. The company has three drug candidates—BBP-418, oral infigratinib, and encaleret—under Priority Review with expected FDA decision dates between late 2026 and mid-2027. A recent $1 billion convertible preferred equity financing strengthens BridgeBio's financial position, supporting upcoming commercial launches and pipeline development while reducing near-term funding risks. This robust growth and pipeline progress underpin the "Strong Buy" rating from analysts.
BridgeBio Pharma shares trade at USD 66.40 on Pluang as of Oct 13, 2026 20:12 WIB, showing a 0.99% gain in one day. The stock's market cap stands at $12.85 billion, with a 52-week range between $53.24 and $90.17. Pluang investors hold the stock for an average of 64 days, with current order activity fully on the buy side.
